| Radicava ORS (edaravone oral) / Mitsubishi Tanabe |
| Terminated | 3b | 384 | Europe, Canada, Japan, US, RoW | MT-1186, Oral edaravone, Placebo | Mitsubishi Tanabe Pharma America Inc. | ALS | 09/23 | 09/23 | | |
| Terminated | 3b | 202 | Europe, Canada, Japan, US, RoW | MT-1186, Oral edaravone, Placebo, Oral | Mitsubishi Tanabe Pharma America Inc. | ALS | 09/23 | 09/23 | | |
2020-000376-38: A Safety Extension Study of Oral Edaravone in Subjects with Amyotrophic Lateral Sclerosis (ALS) Une étude d'extension de la sécurité de l'édaravone par voie orale chez des sujets atteints de sclérose latérale amyotrophique (SLA) |
|
|
| Not yet recruiting | 3 | 140 | Europe | Edaravone, MT-1186, Oral suspension | Mitsubishi Tanabe Pharma Development America, Inc., Mitsubishi Tanabe Development America Inc., Mitsubishi Tanabe Pharma Development America, Inc. | Amyotrophic Lateral Sclerosis (ALS) Sclérose latérale amyotrophique (SLA), A disease that affects nerve cells in the brain and the spinal cord. Maladie qui affecte les cellules nerveuses du cerveau et de la moelleépinière., Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-004256-11: An Efficacy and Safety Study of Oral Edaravone in Subjects with Amyotrophic Lateral Sclerosis (ALS) |
|
|
| Not yet recruiting | 3 | 380 | Europe | Edaravone, MT-1186, Oral suspension | Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), Mitsubishi Tanabe Development America Inc., Mitsubishi Tanabe Pharma Development America, Inc. | Amyotrophic Lateral Sclerosis (ALS), A disease that affects nerve cells in the brain and the spinal cord., Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-002108-41: A Safety Study of Oral Edaravone in Subjects with Amyotrophic Lateral Sclerosis (ALS) |
|
|
| Not yet recruiting | 3 | 150 | Europe | Edaravone, MT-1186, Oral suspension | Mitsubishi Tanabe Pharma Development America, Inc., Mitsubishi Tanabe Development America Inc., Mitsubishi Tanabe Pharma Development America, Inc. | Amyotrophic Lateral Sclerosis (ALS), A disease that affects nerve cells in the brain and the spinal cord., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05568615: Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS |
|
|
| Completed | 3 | 15 | Japan | MT-1186, Edaravone | Mitsubishi Tanabe Pharma Corporation | ALS | 06/23 | 06/23 | | |
MT-1186-A03, NCT04577404: Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) |
|
|
| Completed | 3 | 124 | Europe, Canada, Japan, US | MT-1186, Oral Edaravone | Mitsubishi Tanabe Pharma America Inc. | Amyotrophic Lateral Sclerosis (ALS) | 08/23 | 08/23 | | |
NCT06107205: Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects |
|
|
| Completed | 1 | 29 | US | TTYP01, Edaravone tablets, Radicava, Edaravone injection, Radicava ORS, Edaravone ORS | Auzone Biological Technology Pty Ltd | Healthy Adult Subjects | 12/23 | 12/23 | | |
| Active, not recruiting | N/A | 300 | Canada, US | Edaravone (Radicava®/Radicava ORS®), Radicava®, Radicava ORS® | Mitsubishi Tanabe Pharma America Inc., Massachusetts General Hospital | Amyotrophic Lateral Sclerosis, ALS | 03/24 | 03/24 | | |
